S&P futures firmer pre-open as earnings optimism outweighs rate jitters into blockbuster week
SpaceX (SPCX) trading near $108 into Tuesday's first-ever public earnings; 20% insider unlock two sessions later
10-year yield holding 4.67%; Fed funds futures still price 64% September hike
Brent near $92 on cooling Iran tensions; oil desks flag long-Iran trade "getting trickier" into new week
Today's question: When five different catalysts land in the same five days, which two actually change what a retiree portfolio should hold — and which three are noise you can skip without missing anything?
SpaceX (SPCX) reports its first-ever quarterly as a public company Tuesday after the close. Consensus revenue $6.82 billion. The number the tape will trade off is not revenue — it's Starlink subscriber growth and ARPU. See Theme 1.
Palantir (PLTR) reports Tuesday night as well. Two AI-story earnings in the same session gives us the cleanest read on services-AI vs infrastructure-AI in months. See Theme 2.
Eli Lilly (LLY) prints Wednesday, with weight-loss drugs on pace for roughly $13 billion in the quarter. Any healthcare-ETF-holder has LLY at outsized weight. See Theme 3.
The Fed's June dot plot showed nine of eighteen participants penciling in at least one 2026 rate hike. Wednesday's three-way hawkish dissent was consistent with a much broader hawkish tilt on the committee. See Theme 4.
Jobs report Friday: consensus 91,000 payrolls, unemployment 4.3%. The print resolves whether Warsh has the labor-market slack he wants to leave rates alone into Jackson Hole. See Theme 5.
Five separate catalysts land in the next five sessions. SpaceX prints its first-ever public quarterly Tuesday night, alongside Palantir on the same day. Eli Lilly reports Wednesday, with the weight-loss story either extending or breaking. AMD prints the same day, giving the second read on hyperscaler capex landing at the chip end. Friday closes the week with the July jobs report — the first labor-market data the Fed's hawks can use to justify or reverse their case for a September hike. Most retirees do not need to trade every one of these. Some of them change what your portfolio should hold. The other ones are noise. The map for the week is below.
SpaceX (ticker SPCX) reports its first-ever public quarterly Tuesday after the close. Wall Street consensus is looking for roughly $6.82 billion in Q2 revenue, up from $4.7 billion in Q1. That is a beat-or-miss headline the tape will react to for one session. The number that matters longer than one session is Starlink subscriber growth — 10.3 million at year-end 2025 from 8.9 million a year earlier — combined with Starlink's average revenue per user, which has slid from around $99 monthly in 2023 to roughly $66 in Q1 2026. If subscribers keep growing but ARPU keeps dropping, the growth story that supports a $1.4 trillion valuation starts to look like a volume story pretending to be a pricing story.
Two trading days after SPCX prints, twenty percent of eligible insider and employee shares unlock. That is mechanical selling pressure regardless of the earnings outcome. If Tuesday's print beats and management guidance is credible, the unlock is absorbed. If Tuesday's print misses or the Starlink ARPU decline accelerates, the unlock lands into an already-weak tape and the reflexive selling compounds. For a retiree who holds SPCX only through broad-market ETFs, this is a pass-through event — the ETF absorbs whatever price the tape prints. For any retiree who added direct SPCX exposure since the IPO, this week is when the position is either validated or reset.
Watching: SPCX into Tuesday's close and the 48 hours after; SPY / VOO for index-inclusion effect.
Bias: Neutral into the print for direct holders; awareness-only for index-holders. The 20% insider unlock two sessions later is the asymmetric event, not the print itself.
Risk note: if Starlink ARPU trends below $60 in the reported quarter, the multiple compression that follows will not be a one-session move. Size direct exposure accordingly.
Palantir (PLTR) also reports Tuesday after the close. That gives the market two AI-story earnings in the same session — SpaceX on the infrastructure side (Starlink, launch, connectivity), Palantir on the services side (data operations for the government-and-large-enterprise buyer). Last week's earnings gave us the hyperscaler capex numbers — Microsoft's fiscal-2027 capex guide at $255-260 billion, Amazon's AWS growing 37%. Tuesday tells us whether that capex is actually landing in the AI-services layer that the retiree portfolio owns most often through diversified tech ETFs.
What to read for is the language Palantir uses about government contract renewals and commercial-segment growth. If Palantir shows accelerating commercial revenue and confirms multi-year government contracts, the read-through is bullish for the whole AI-services complex — and for the infrastructure names funded by that spend. If Palantir shows commercial deceleration, the market will start pricing an AI-services glut, and the hyperscaler capex boom becomes a supply-side story with no clear demand pull. Same week. Same complex. Two very different trades.
Watching: PLTR, AMD (Wednesday), plus SMH / SOXX for chip-sector read-through.
Bias: Neutral into Tuesday's print; look for hyperscaler-benefiter language in the call. Palantir's commercial-vs-government mix on the guidance is the tell.
Risk note: PLTR has a persistent retail-hype tail that can push single-session moves double what fundamentals justify. Don't chase either direction in the first hour after print.
Eli Lilly (LLY) reports Wednesday morning, and the weight-loss drug segment is on pace to bring in roughly $13 billion in the quarter alone. Options-market pricing implies a 6.9% single-session move on the print, which is unusually wide for a mega-cap healthcare name. The reason the print carries this much weight is that Lilly is the single largest position in the S&P 500 Health Care sector ETF (XLV) and one of the top holdings in most broad healthcare index products. If you hold XLV, or a healthcare sleeve inside a target-date retirement fund, Lilly's earnings result flows directly through to your Wednesday close.
What the tape is really pricing into Wednesday is not just the current quarter. It is the trajectory question: does the weight-loss market keep expanding at the pace 2024 and 2025 suggested, or does the competitive entry from Novo Nordisk and the emerging generic-adjacent options start to compress the pricing power? Lilly has to guide to a market that stays big enough to support a valuation that is already priced for continued dominance. The risk-reward around the print is asymmetric in a way that matters for anyone who wandered into a "safe healthcare ETF" and did not check the LLY concentration on the way in.
Watching: LLY, XLV, plus NVO for competitive-read-through.
Bias: Neutral into print; concentration-awareness for ETF holders. Not a "buy or sell Lilly" question — a "how much of my healthcare exposure is actually Lilly" question.
Risk note: a 7% single-session move in a top-5 S&P holding will drag the whole index. If LLY misses hard, expect broader-market weakness Wednesday afternoon regardless of AMD's after-close print.
🔒 OBBBA Rule Watch: Tax Rule of the Day
Rule 9: RMD Strategy Under Permanent TCJA Brackets
Required Minimum Distributions from traditional IRAs and 401(k)s used to be a "take what the IRS makes you take" event with limited planning flexibility. Now that the Tax Cuts and Jobs Act brackets are permanent under OBBBA — the 10%, 12%, 22%, 24%, 32%, 35%, and 37% structure — the multi-year RMD planning horizon changes. Instead of treating each RMD year in isolation against a "sunset that may come," retirees can now plan a fifteen- or twenty-year distribution schedule against a stable bracket regime. That opens strategies that were previously too uncertain to commit to: partial Roth conversions in the 22% bracket to reduce future RMD size, spreading capital gains harvests across multiple years to stay under the 32% threshold, and timing charitable distributions (QCDs) against the years an RMD would otherwise push into a higher bracket. None of these strategies work in a one-year snapshot. They work only against a multi-year plan, which the permanent brackets now let you build.
Why it matters: With the 10-year Treasury at 4.67% and the Fed openly hawkish, higher-for-longer rates change the after-tax yield on bond-heavy portfolios. RMD sequencing under permanent brackets is one of the few levers still fully under a retiree's control that can meaningfully move the after-tax outcome over a decade.
Wednesday's three-way hawkish dissent from the FOMC was not the whole picture on how the committee actually leans. The June dot plot — the individual projections each FOMC participant submits alongside the meeting decision — showed nine of eighteen participants penciling in at least one rate hike for 2026. That is half the committee. The three dissenters last week were simply the most public voices for a position the majority of the committee already carries privately. Fed funds futures now price a 64% probability of a September hike, up from around 20% a month ago, which means the market has already absorbed roughly two-thirds of the way toward pricing the dot plot's median view.
What this means for a retiree portfolio is that the risk premium on long-duration Treasury exposure just moved. If the majority of the FOMC actually acts on the hike, the 10-year moves higher and TLT-type positions mark down again. If they hold, the position pays as it stands. Either way, the risk is asymmetric — you are paying a duration premium against a committee that is telegraphing higher rates. What this means for your IRA: check the duration of any bond fund labeled "total return" or "aggregate." If the duration is above six years and you cannot articulate why, the position is probably drifting past what you are being paid to hold.
Watching: TLT, AGG, BND, plus HYG for credit read.
Bias: Defensive on long-duration; neutral on 3-7 year; constructive on short-duration Treasury and floating-rate. Match the duration to the compensation.
Risk note: a soft Friday jobs report (below 60K payrolls, unemployment 4.4%+) would reverse this trade quickly. The Fed hawks lose their justification if the labor market cracks.
Five catalysts in five days does not mean a retiree portfolio needs five trades. The two prints that actually change portfolio construction for a 55-to-75-year-old holder are Friday's jobs report (because it moves the bond sleeve) and Wednesday's Eli Lilly print (because it moves the healthcare concentration inside index products). SpaceX is a direct-exposure decision, not an index-holder event. Palantir is a signal read for AI-services allocation, not a required trade. AMD is a chip-cycle datapoint, useful for context but not a portfolio-mover for most retirees. The discipline this week is not "which trade do I take." It is "which three catalysts do I read the recap of without doing anything."
Watching: your own bond-duration and healthcare-ETF concentration this weekend.
Bias: Sleeve consideration only. Discipline is not doing more; discipline is knowing which reports demand action and which are context.
Risk note: attention has a cost. Every catalyst you actively trade this week is a catalyst you gave account energy to that could have been better spent on the two that actually matter.
TICKER | THEME | BIAS | ACTION |
|---|---|---|---|
SPCX | First public quarterly Tue | Neutral direct; awareness index | Watch Starlink ARPU and 48-hour unlock reaction |
PLTR | AI-services read Tue | Neutral into print | Don't chase first-hour move either direction |
LLY / XLV | Weight-loss print Wed | Neutral; concentration-check ETF holders | Check your XLV weighting before Wednesday close |
TLT / AGG | Duration risk under hawkish Fed | 🔴 Defensive long duration | Match duration to compensation received |
Attention | Five catalysts, two that matter | Discipline only | Read the other three recaps; don't trade them |
For informational purposes only. Not investment advice. Past performance is not indicative of future results. Bastion Stability is a daily defensive briefing for retirees and pre-retirees and does not provide individualized tax or investment advice; consult a licensed advisor before making any decision relating to your retirement accounts.